Experimental Works

Prednisolone and Vitamin D₃ Modulate Oxidative Metabolism and Cell Death Pathways in Blood and Bone Marrow Mononuclear Cells


Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv; e-mail: ishymansk@inbox.ru

The study was designed to evaluate reactive oxygen species (ROS)/nitric oxide (NO) formation and apoptotic/necrotic cell death elicited by prednisolone in peripheral blood and bone marrow mononuclear cells and to define the efficacy of vitamin D₃ to counter glucocorticoid (GC)-induced changes. It was shown that prednisolone (5 mg per kg of female Wistar rat’s body weight for 30 days) evoked ROS and NO overproduction by blood mononuclear cells (monocytes and lymphocytes) that correlated with increased cell apoptosis and necrosis. In contrast, prednisolone did not affect ROS/NO levels in bone marrow mononuclear cells that corresponded to lower level of cell death than in the control. Alterations of prooxidant processes revealed in mononuclear cells and associated with GC action were accompanied by vitamin D₃ deficiency in animals, which was assessed by the decreased level of blood serum 25-hydroxivitamin D₃ (25OHD₃). Vitamin D₃ administration (100 IU per rat daily for 30 days, concurrently with prednisolone administration) completely restored 25OHD₃ content to the control values and significantly reversed ROS and NO formation in blood mononuclear cells, thus leading to decreased apoptosis. In bone marrow, vitamin D₃ activated ROS/NO production and protein nitration that may play a role in prevention of prednisolone-elicited increase in bone resorption. We conclude that vitamin D₃ shows a profound protection against GC-associated cellular damage through regulating intracellular ROS/NO formation and cell death pathways.

Key words: osteoporosis, prednisolone, vitamin D₃, blood/bone marrow mononuclear cells, reactive oxygen/nitrogen species, nitric oxide, apoptosis, necrosis.

Several adverse effects caused by long-term glucocorticoid (GC) therapy are emerging health problem that limits GC use for the treatment of patients with various inflammatory and autoimmune diseases, allergies and lymphoproliferative disorders. Osteoporosis is among the most devastating side effects of chronic GC administration associated with significant alterations of mineral metabolism and bone formation [1]. Glucocorticoid-induced osteoporosis causes an increase in bone fractures, delays healing of fractures, and affects the quality of life.

It is known that osteoblasts, together with osteoclasts, control the amount of bone tissue and regulate bone remodeling. The underlying mechanism of osteoporosis is associated with the prevalence of osteoclast-dependent bone resorption over its osteoblast-mediated formation and mineralization leading to loss of bone mass and mineral density [1]. GCs modify osteoblastic and osteoclastic cell differentiation, number, and function either directly or via influencing the recruitment of their precursors from the bone marrow [2]. Osteoblasts were shown to be originated from bone marrow mesenchymal progenitor cells. Multinucleated osteoclasts are the principle bone resorbing cells that derive from hematopoietic precursors of the monocytic lineage common to peripheral blood monocytes, macrophages and myeloid dendritic cells. Pre-osteoclasts circulate in monocyte fraction of the peripheral blood until they reach the sites of bone resorption.

A common pathologic feature of GC-induced cell disturbances is the development of oxidative stress. Although the effects of prednisolone on cell
function are largely mediated through glucocorticoid receptors and metabolic changes, recent studies have demonstrated the involvement of reactive oxygen (ROS)/nitrogen species (RNS)-induced modifications of critical cellular macromolecules in modulation of signal transduction cascades and cell death pathways [3]. We have previously described and discussed the pathological role of synthetic glucocorticoid prednisolone in activation of ROS/RNS-mediated hepatocellular death [4]. Currently, insufficient attention was focused on the generation of active metabolites of oxygen and nitrogen in progenitor cells as one of the major determinants contributing to cell dysfunction and abnormalities of bone remodeling.

Alleviating excessive prooxidant reactions might be a promising strategy to prevent or delay the onset of pathological changes induced by GCs. The positive effects of vitamin D₃ (cholecalciferol) in maintaining functional activity of different cells may be useful in correcting cellular dysfunction caused by glucocorticoid therapy. Being a ligand for nuclear receptor (VDR), the hormonally active form of vitamin D₃ (1,25(OH)₂D₃) regulates the expression of a variety of nuclear genes [5]. The recent discovery of VDR in different cell types has expanded the known function of 1,25(OH)₂D₃ from a role in calcium homeostasis to physiological process of bone formation/resorption and immune cell modulation. Vitamin D₃ acting via VDR has been implicated in the mechanisms by which cells proliferate, differentiate, become functionally active or die [6]. Nevertheless, the possible pathogenetic role of impaired vitamin D₃ metabolism in the mechanism of GC-induced side effects on bone tissue remodeling still requires better understanding.

Growing evidence suggests that inadequate supply with vitamin D₃ is a crucial factor that significantly increases the risk of a number of common pathologies, such as cancer, cardiovascular, infectious, autoimmune and diabetes mellitus [6]. We have recently found that chronic liver injury associated with long-term prednisolone action can be a major cause of vitamin D₃ deficiency because liver is known to play a principle role in the synthesis of the hormone – 25OHD₃ [4]. Available scientific data also show that vitamin D₃ possesses direct and indirect antioxidative effects in normal and diseased states, effectively inhibiting lipid peroxidation and oxidative damage to proteins in cells of different types, that leads at the structural level to improvement and better preservation of cellular integrity (cell protective effect) and restoration of functional activity of damaged cells [7]. Vitamin D₃ is thought to provide anti-inflammatory, immunomodulatory and cytotoxic effects in various tissues [5, 6]. However, there is a lack of consistent information regarding the vitamin D₃ ability to prevent ROS/RNS-mediated cell dysfunction associated with the deleterious effects of long-term prednisolone administration in bone marrow.

The present study was therefore aimed at investigating prednisolone-associated modulation of ROS/nitric oxide (NO) formation and cell death pathways in mononuclear cells from peripheral blood and bone marrow and to evaluate how vitamin D₃ administered concurrently with prednisolone attenuates GC-induced disturbances.

Materials and Methods

Animals. Female Wistar rats weighing 100 ± 5 g had unrestricted access to food and water and were housed in temperature and humidity controlled rooms. Animals were randomly divided into 3 groups: 1 – control rats (n = 8); 2 – rats that orally received prednisolone at a dose 5 mg/kg of body weight (daily for 30 days, n = 8); 3 – rats that orally received prednisolone at a dose 5 mg/kg of body weight and 100 IU of vitamin D₃ (daily for 30 days, n = 8). All animal procedures were performed in accordance with international recommendations of the European Convention for the Protection of Vertebrate Animals used for Research and Scientific Purposes (Strasbourg, 1986), General Ethical Principles of Animal Experimentation, approved by the First National Congress on Bioethics (Kyiv, 2001).

Peripheral blood and bone marrow mononuclear cell isolation. Peripheral blood mononuclear cells were isolated using Histopaque-1083 (Sigma, USA) in accordance with the standard manufacturer’s protocol. Bone marrow cells were obtained as briefly described below. Rat femurs were excised, dissected and bone marrow cells were harvested by repeated flushing of the femoral cavities with 1 ml syringe using phosphate-buffered saline (PBS) 10 times. Total marrow isolate was collected by centrifugation at 400 g for 1 min at 4 °C and resuspended in PBS. The resultant cell suspension was filtered through successive 70 and 40 µm nylon cell strainers followed by washes at 400 g for 5 min at 4 °C. Subsequently, red blood cells (RBC) were lysed with RBC Lysis Buffer and the bone marrow mononuclear cells were washed twice, centrifuged and final pellet was resuspended in PBS.
Serum 25OHD₃. Blood was obtained by cardiac puncture for mononuclear cells isolation and analysis of serum 25-hydroxyvitamin D₃ (25OHD₃). The content of 25-hydroxyvitamin D₃ in serum was assayed using a commercial ELISA kit (The IDS 25-Hydroxy Vitamin D EIA, USA) as described by the manufacturer’s protocol.

DCFH oxidation measurement. Fluorescence detection of intracellular reactive oxygen species (ROS) production was analyzed using the fluorescent probe 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA; Sigma, USA). ROS generated by cells oxidizes DCFH-DA to produce highly fluorescent green compound (2′,7′-dichlorofluorescein). Isolated cells (approximately 0.5·10⁶) were incubated in Hank's balanced salt solution with DCFH-DA concentration of 10 µM for 30 min (37 °C) in a humidified atmosphere of 5% CO₂. Subsequently, the cells were washed, centrifuged, resuspended and fluorescence was measured with an EPICS XLTM flow cytometer (Beckman Coulter, USA) using the excitation/emission wavelengths of 485/530 nm. Results were expressed as a relative fluorescence of the samples in comparison to control. Analysis of the results of all studies obtained by flow cytometry was performed using the FCS Express V3 software.

Evaluation of nitric oxide synthesis. Intracellular nitric oxide production in isolated cells was estimated using the specific fluorescent probe 4,5-diaminofluorescein diacetate (DAF-2DA; Sigma, USA). Upon entering the cells, the diacetate bond of the probe is cleaved by intracellular esterases liberating DAF, which specifically reacts with the nitric oxide (nitronitrosative agents p-coumaric acid (Sigma, USA) and luminol (AppliChem GmbH, Germany). To provide equal protein loading, membranes were incubated with horseradish-peroxidase conjugated anti-mouse secondary antibody (1:1000 for 1 h at room temperature. The membrane was than incubated with phosphate-buffered saline containing 5% fat-free milk and 0.05% Tween-20 for 1h at room temperature. The bands were visualized by enhanced chemiluminescence agents p-coumaric acid (Sigma, USA) and luminol (AppliChem GmbH, Germany). To provide equal protein loading, membranes were incubated with anti-β-actin peroxidase conjugated antibody (1:50 000; Sigma, USA) overnight at 4°C. After extensive washing, the membrane was incubated with horseradish-peroxidase conjugated anti-mouse secondary antibody (1:50 000; Sigma, USA) for 1 h. The immunoreactive bands were quantified with Gel-Pro Analyzer 32.

Statistics. Data are expressed as mean ± SEM for at least six rats per group. Student’s t-test was used for all analyses and values of P < 0.05 were considered to indicate statistically significant difference. All calculations were performed using the Microsoft Excel software for t-test analysis.

Results and Discussion

As a close relation exists between vitamin D₃ deficiency and increased risk of most deleterious side effects induced by glucocorticoids, we conducted an assessment of 25-hydroxyvitamin D₃ (25OHD₃₃) level in blood serum as a reliable biomarker of vitamin D₃ bioavailability. Those rats that chronically received prednisolone demonstrated severe vitamin D₃ deficiency, since more than 2.5-fold decrease in 25OHD₃ was found in blood serum compared with the control group (Fig. 1).
These results indicate the negative effect of prednisone on the metabolism of cholecalciferol, which may be linked to significant changes in protein content and activity of vitamin D$_3$ 25-hydroxy-lase isoenzymes in liver cells that we have previously established [9]. Vitamin D$_3$ treatment led to complete restoration of 25OHD$_3$ level. On the background of prednisolone-induced impairment of vitamin D$_3$ metabolism and D$_3$-deficiency significant changes in oxidative metabolism were detected.

Oxidative/nitrosative stress associated with increased generation of reactive oxygen and nitrogen species as well as impaired effectiveness of antioxidant defense has recently been recognized as one of the key mechanisms in the pathogenesis of various disorders associated with 25OHD$_3$ deficiency [10]. To clarify whether alterations of oxidative metabolism are involved in the development of cellular dysfunction associated with GCs, we examined the levels of free radicals formation in mononuclear cells isolated from peripheral blood and bone marrow using DCFH-DA. As DCFH-DA has no specificity in detecting actual oxygen species [11], we use the term ROS as it is generally accepted to encompass the initial species generated by oxygen reduction, as well as their secondary reactive products. DCFH oxidation that reflects the intensity of pro-oxidant processes in cells, are presented in Table 1.

It was found that chronic administration of prednisolone stimulated ROS production in isolated blood mononuclear cells by 35% compared with the control animals. Vitamin D$_3$ treatment showed antagonistic effect on the level of ROS generation induced by glucocorticoid hormone. In contrast to mononuclear blood cells, the rate of ROS formation in bone marrow cells remained unchanged after prednisolone administration. Despite the fact that prednisolone had no influence on ROS production in bone marrow cells, vitamin D$_3$ treatment slightly increased the level of intracellular oxidants when compared with the control and GC-administered groups.

Cytotoxic and mutagenic effects of ROS/RNS are caused by increased free radical oxidation of physiologically important macromolecules. Moreover, redox modulation of cellular signaling by NO is central to regulation of cell proliferation, differentiation and death pathways. To assess the potential involvement of nitric oxide and its metabolites in the mechanism of prednisolone-induced changes we next investigated the levels of NO production by isolated cells. It was found using NO-sensitive fluorescent probe, DAF-2DA, that administration of prednisolone results in a significant elevation of NO synthesis in blood mononuclear cells (by 30%) as compared with controls (Fig. 2).

Vitamin D$_3$ diminished the level of NO formation in these cells compared with the group of animals administered with the glucocorticoid. Similarly

![Fig. 1. Effects of prednisolone and vitamin D$_3$ administration on 25-hydroxyvitamin D$_3$ level in blood serum of three animal groups: 1 – control; 2 – prednisolone administration; 3 – prednisolone and vitamin D$_3$ administration. All data are presented as mean ± SEM (n = 8); * P < 0.05 vs. control, # P < 0.05 vs. prednisolone administration.](image-url)
to what we observed in the case of DCFH oxidation, no changes in nitric oxide formation were seen in bone marrow cells in the group of animals that received prednisolone (Fig. 3). Vitamin D₃ treatment enhanced NO production to the level almost 2.5-fold as much as in the control group.

Given that free oxygen and nitrogen species under the conditions of their excess production can mediate either regulatory or cytotoxic effects on cells, it was essential to define whether dependence exists between the intensity of ROS/RNS formation and cell death following prednisolone and vi-
tamin D$_3$ administration. Quantitative evaluation of apoptosis and necrosis using Annexin V-EGFP/PI double staining was analyzed by flow cytometry. As shown in Table 2, the rate of blood mononuclear cells with apoptosis and necrosis raised to 14.70 and 10.52% of total cells after prednisolone administration compared with 11.50 and 7.91% in control rats, respectively. Treatment with vitamin D$_3$ prevented prednisolone-induced apoptosis without affecting cell necrosis. Prednisolone provided opposite effect on cell death within the bone marrow as compared with peripheral blood mononuclear cells. Following prednisolone administration, a significant reduction of Annexin V-EGFP$^+$ and PI$^+$ cells to 6.87 and 0.95% from 12.85 and 2.07% in control was established. Vitamin D$_3$ caused a marked increase in apoptotic cell death compared with prednisolone without influencing the number of necrotic cells.

Apoptosis in rat bone marrow cells after vitamin D$_3$ treatment can potentially be ascribed to excess ROS/RNS production. To further confirm that the occurring cell death correlates with oxidative-nitrosative damage to biomolecules, we measured the level of 3-nitrotyrosine by western blotting (Fig. 4).

It is known that tyrosine residues of proteins are sensitive targets for the active nitrating agent peroxynitrite (ONOO$^{-}$), which is formed by interaction of nitric oxide with superoxide anion radicals. Therefore, the content of 3-nitrotyrosine is regarded as a specific and reliable marker of nitrosative stress. As Fig. 4 depicts, there was no difference in protein nitration between prednisolone-administered and control groups. Compared with prednisolone-administered rats, bone marrow cells displayed a 2.3-fold induction of nitrosylated proteins after cholescalciferol treatment that corresponds to the level of ROS and NO production by these cells.

Collectively, our findings indicate the development of essential prednisolone-induced alterations of oxidative metabolism and cell death pathways that can be discussed from two following points of view, namely (1) how discrepancies in the effects of prednisolone and cholescalciferol on ROS/RNS production in blood cells and bone marrow cells can be interpreted; and (2) what the functional consequences of the described disturbances could be for bone formation/resorption.

Revealed alterations of oxidative metabolism elicited by chronic prednisolone administration are clearly consistent with the results of cell dysfunction published previously [3, 12]. Excessive GCs-evoked production of ROS and oxidative stress were observed in a variety of cell types [13, 14]. By contrast, recent evidence also suggests a protective role of hormonal therapy against oxidative damage to cells [15]. Discrepancies in glucocorticoid ability to modulate pro-/antioxidant status of cells could be accounted for by different experimental conditions. They include doses and administration routes, experimental models, endogenous versus exogenous GC excess, underlying disease for which GCs were administered; and most importantly, there is increa-

---

**Table 2. Evaluation of apoptotic (Annexin V-EGFP-positive) and necrotic (PI-positive) mononuclear cells isolated from rat bone marrow and peripheral blood after prednisolone and vitamin D$_3$ administration, (M ± m; n = 8)**

<table>
<thead>
<tr>
<th>Group</th>
<th>Control</th>
<th>Prednisolone administration</th>
<th>Prednisolone and vitamin D$_3$ administration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Annexin V-EGFP, %</td>
<td>PI$^+$, %</td>
<td>Annexin V-EGFP, %</td>
</tr>
<tr>
<td>Blood mononuclear cells</td>
<td>11.50 ± 1.02</td>
<td>7.91 ± 0.45</td>
<td>14.70 ± 1.31*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>10.52 ± 0.84*</td>
</tr>
<tr>
<td>Bone marrow mononuclear cells</td>
<td>12.85 ± 1.09</td>
<td>2.07 ± 0.13</td>
<td>6.87 ± 0.49*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.95 ± 0.06*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>8.12 ± 0.63*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.78 ± 0.04*</td>
</tr>
</tbody>
</table>

Note: Mononuclear cells from bone marrow and peripheral blood were stained by Annexin V-EGFP and PI and analyzed by flow cytometry. Summarized data of all measurements are presented as mean (fluorescence intensity, a.u.) ± SEM, * $P < 0.05$ vs. control, $^*$ $P < 0.05$ vs. prednisolone administration.
Fig. 4. Effects of prednisolone and vitamin D₃ administration on the levels of nitrated proteins in bone marrow: 1 – control; 2 – prednisolone administration; 3 – prednisolone and vitamin D₃ administration. Western blot analysis of total bone marrow lysates was performed using the antibody against 3-nitrotyrosine. Representative immunoblot (A) and quantification of three experiments (B) are shown. The mean protein expression level was quantified as the sum of the densities of immunoreactive bands in each track corresponding to proteins with molecular masses from 50 to 130 kDa. Protein levels were normalized to β-actin. All data are shown as mean ± SEM (n = 6); *P < 0.05 vs. control, #P < 0.05 vs. prednisolone administration.

Sing evidence that early effects may be opposite to effects of prolonged GC action in therapeutically relevant doses.

We can hypothesize that negative impact of chronically administered prednisolone on cellular function may be mediated via impaired interaction of glucocorticoid receptors with prooxidant and/or inflammatory transcription factors to repress transcriptional activity, i.e. transrepression. More recently it has been proposed that transrepression mediates most of the beneficial effects of GCs, whereas transactivation promotes most of their adverse effects [16]. The possible reason for prednisolone-associated cell injury may lie in the inhibitory glucocorticoid action on the expression of factors that not only facilitate ROS/RNS formation but also reduce or limit oxidative stress.

In the present study we followed the prevention paradigm to diminish pathogenic changes caused by chronic administration of prednisolone using concurrent vitamin D₃ treatment. Our results have clearly shown the antioxidant effect of vitamin D₃ in blood mononuclear cells, while prooxidant action of cholecalciferol on bone marrow progenitor cells was observed. The potent antioxidant activity of vitamin D₃ has been reported by others [6, 7]. At the same time several studies also suggest an increase in ROS/RNS production [17]. The dual behavior revealed in different tissues shows that the outcome from challenge with an oxidative stress may have relevance to the integration of a series of intracellular signaling mechanisms that depending on cell type involved could both protect against or promote oxidative-nitrosative stress. Modulation of oxidative metabolism by vitamin D₃ can largely be mediated by the effects of its hormonally active metabolite – 1,25-dihydroxyvitamin D₃ through VDR [5]. Overall, vitamin D₃ may effectively regulate the rate of free radicals formation in liver cells and their survival via changes of pro/antioxidant and pro/anti-apoptotic genes expression [5-7].

Our data may also have significance for understanding a pivotal role of ROS/RNS in osteoblast and osteoclast formation from progenitor marrow cells in the regulation of bone remodeling by steroids. Although glucocorticoids were shown to inhibit bone formation through increasing the death of mature osteoblasts and blocking osteoblastic differentiation from precursor cells, the character of steroid action on osteoclast activity and bone resorption is still a controversial subject. Sustained stimulation of bone matrix degradation by isolated osteoclasts incubated with GCs as well as their cytotoxic effects on osteoclasts have been reported in recent studies [18]. The increase in osteoclast-mediated bone resorption is likely responsible for the initial bone destruction
after GC administration. In contrast, chronic exposure of high GC doses has inhibiting effects both on bone formation and resorption [19] that largely corresponds to experimental design of the present investigation. Notably, prednisolone-induced pathological changes in bone tissue were confirmed in our previous studies by assessment of bone formation/resorption markers indicative of osteoporosis development.

In spite of the fact that there is still no clear explanation for a direct effect of GCs on osteoclastic precursors, GCs could modulate recruitment of osteoclasts. Our findings may suggest that pre-osteoclast maturation rather than their formation is impaired in GC-induced osteoporosis. Demonstrated here decreasing effect of prednisolone on apoptosis of bone marrow cells that occurs concomitantly with unchanged rate of ROS/RNS production, most likely reflects the enhancement of bone marrow cells proliferation. As osteoclasts are formed from marrow-derived cells that circulate in the monocyte fraction, we also isolated blood mononuclear cells enriched in monocytes to evaluate oxidative metabolism and apoptosis. An increase in oxidative stress and apoptotic death of blood mononuclears suggests a possible prednisolone-induced inhibition of osteoclast differentiation from an early stage of circulating precursor cells. Together, these data are in accordance with a systemic suppression of osteoclast activation by prednisolone that can be related to glucocorticoid influence on early precursors of osteoclasts in the bone marrow and their subsequent differentiation rather than on mature osteoclasts of bone tissue.

It seems quite likely that vitamin D₃ can abrogate prednisolone-induced disruptions of key steps in the differentiation and activation of osteoblasts or/and osteoclasts by modulating intracellular redox state as well as survival and death pathways in progenitor cells. Based on the evidence that reactive oxygen species act as signal mediators in cell differentiation, the established ability of vitamin D₃ to induce ROS and NO production in bone marrow may suggest additional role for cholecalciferol, beyond its capacity to increase bone mineralization, to promote osteoblast/osteoclast differentiation from hematopoietic precursors. Simultaneous increase in osteoblast and osteoclast formation with subsequent activation of these cells naturally can lead to augmentation of bone turnover that ameliorate prednisolone-evoked loss of bone mass and mineral density. Because of the recent observation that nitric oxide can counter prednisolone-induced osteoporosis [20], induction of NO synthesis in bone marrow cells by cholecalciferol can also be referred to as an important mechanism of osteotropic action of vitamin D₃.

In summary, the present study provides support for ROS/RNS and mononuclear cells from blood and bone marrow as therapeutic targets in prednisolone-induced osteoporosis. It was shown that ROS/nitric oxide production and cell death are differentially regulated by prednisolone depending on cell type. All the alterations associated with GC action were accompanied by vitamin D₃ deficient state of animal organism. Vitamin D₃ co-administration with prednisolone and restoration of 25OHD₃ content may prevent osteoporosis by normalizing impaired oxidative metabolism in mononuclear blood cells and stimulating NO pathway in bone marrow cells. This indicates that vitamin D₃ has potential usefulness in the prevention and/or treatment of pathological changes associated with the chronic administration of glucocorticoids.

ПРЕДНІЗОЛОН І ВІТАМІН D₃ МОДУЮТЬ ОКИСНИЙ МЕТАБОЛІЗМ І ШЛЯХИ КЛІТИННОЇ ЗАГИБЕЛІ МОНОНУКЛЕАРИВ КРОВІ ТА КІСТКОВОГО МОЗКУ

І. О. Шиманський, О. О. Лісаковська, А. О. Мазанова, Д. О. Лабузинський, А. В. Хоменко, М. М. Великий

Інститут біохімії ім. О.В. Палладіна, НАН України, Київ; e-mail: ishmansk@inbox.ru

Проведено оцінку інтенсивності генерування активних форм кисню (ROS)/оксиду азоту (NO) і шляхів апоптичної/некротичної загибелі мононуклеарів периферичної крові та кісткового мозку за дії преднізолону і встановлено ефективність вітаміну D₃ у запобіганні розвитку глюкокортикоїді (GC)-індукуваних порушень. Показано, що введення преднізолону (5 мг на 1 кг маси тіла щурів-самиць лінії Wistar протягом 30 днів) зумовлювало надмірне продукування ROS та NO в мононуклеарах крові (моноцити і лімфоцити), що корелювало з підвищенням рівнями апоптичної і некротичної загибелі клітин. На противагу цьому, преднізолон не впливав на генерування ROS/NO в мононуклеарах крові.

I. O. Shymanskyy, O. O. Lisakovska, A. O. Mazanova et al.
клерач кісткового мозку, що приводило до зниження рівня загибелі клітин у порівнянні з контролем. Виявлена зміни прооксидантних процесів супроводжувалися розвитком дефіциту вітаміну D₃ у тварин, який оцінювали за зниженням концентрації сироваткового 25OHD₃. Введення шурам вітаміну D₃ (100 МО в день протягом 30 днів одноразово із введенням преднизолону) повністю відновлювало вміст 25OHD₃, до рівня контролльних значень та істотно знижувало продукування ROS і NO в клітинах крові, що приводило до зниження їх апоптозу. У клітинах кісткового мозку введення вітаміну D₃ спричинювало зниження концентрації активних форм кисню і азоту, що відіграє роль у запобіганні індукуваної преднизолоном інтенсифікації резорбції кісткової тканини. Таким чином, вітамін D₃ ефективно протидіє пошкодженню клітин, асоційованому із тривалим введенням преднизолону, забезпечуючи регуляторний вплив на формування ROS/NO та шляхи клітинної загибелі.

Ключові слова: остеопороз, преднизолон, вітамін D₃, мононуклеари крові/кісткового мозку, активні форми кисню/азоту, оксид азоту, апоптоз, некроз.

References


Received 28.09.2016